According to author calculation, if drug milk levels were at the detection limit, the relative infant dose would have averaged 1.12%
The MHRA/EMC SmPC highlights additional important safety concerns including: Risk of pancreatitis (presenting as severe abdominal pain) Gallbladder disease including cholelithiasis Dehydration potentially leading to acute kidney injury Potential worsening of diabetic retinopathy in patients with pre-existing disease, particularly with rapid glycaemic improvement Nutritional considerations are paramount
Eli Lilly is also developing oral GLP-1 receptor agonists, including compounds such as orforglipron, which have shown significant weight loss and glycemic improvements in Phase III clinical trials
How to take them: Best used 30 minutes after a meal or when symptoms start
It does not provide independent evaluation, comparative analysis, or recommendations regarding telehealth providers
How is oral melanoma diagnosed and staged